President Joe Biden and Albert Bourla (Patrick Semansky/AP Images)
A Pfizer win in a heated anti-kickback case could lead to a ‘gold rush’ of biopharma companies subsidizing Medicare drugs, government says
Pfizer on Tuesday made the case for why it should be able to subsidize the cost of one of its rare disease drugs for some …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
